Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

Ann Oncol. 2019 Jun 1;30(6):1018. doi: 10.1093/annonc/mdy530.
No abstract available

Publication types

  • Published Erratum